All In Biotech

Drug Trial Radar · NCT06316973

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Feb 7, 2024

Primary completion

May 30, 2024

Study completion Jun 6, 2024

Sponsor

Lead sponsor
Clear Scientific, Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.

Conditions

  • Substance Use Disorders
  • Methamphetamine Abuse
  • Methamphetamine Intoxication

Interventions

  • CS-1103Drug

    CS-1103 for infusion

  • Sterile SalineDrug

    Sterile Saline for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)Time frame: 3 days plus 8 days for follow-up
  2. Number of Participants by Severity of AEsTime frame: 3 days plus 8 days for follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Vince Clinical Research

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.